Thermo Fisher Scientific Inc. $TMO is Foresight Group Ltd Liability Partnership’s 8th Largest Position

Foresight Group Ltd Liability Partnership raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3,242.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 58,497 shares of the medical research company’s stock after purchasing an additional 56,747 shares during the quarter. Thermo Fisher Scientific accounts for 4.2% of Foresight Group Ltd Liability Partnership’s portfolio, making the stock its 8th largest position. Foresight Group Ltd Liability Partnership’s holdings in Thermo Fisher Scientific were worth $29,113,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $25,000. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.1%

NYSE TMO opened at $477.03 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $180.13 billion, a P/E ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a 50-day moving average of $464.58 and a 200-day moving average of $452.37. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. William Blair assumed coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. HSBC restated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.